Novel therapies and potential therapeutic targets in the management of chronic hepatitis B

Joao M. Serigado, Manhal Izzy, Harmit S. Kalia

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic hepatitis B is a persistent and progressive inflammatory liver disease caused by infection with the hepatitis B virus (HBV). More than 240 million individuals are infected with HBV worldwide and hepatitis B accounts for an estimated 650 000 deaths annually. Approximately up to 30% of chronically infected patients will develop complications of HBV infection including, but not limited to, liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Currently approved therapies have improved clinical outcomes, but have a considerable side-effect profile, elevated cost, and a finite course of treatment. This has led to a growing interest in research for new therapies. As the mechanisms for HBV replication are becoming better understood, new potential targets have been discovered, leading to the development of new therapies. In this article, we describe the promising therapies that are under evaluation, showing their mechanisms of action, effects, and stage of development.

Original languageEnglish (US)
JournalEuropean Journal of Gastroenterology and Hepatology
DOIs
StateAccepted/In press - May 19 2017

Fingerprint

Chronic Hepatitis B
Hepatitis B virus
Therapeutics
End Stage Liver Disease
Virus Diseases
Virus Replication
Hepatitis B
Liver Cirrhosis
Liver Diseases
Hepatocellular Carcinoma
Costs and Cost Analysis
Infection
Research

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

@article{42c1ed0e6eb249fcad6c490c5df146d3,
title = "Novel therapies and potential therapeutic targets in the management of chronic hepatitis B",
abstract = "Chronic hepatitis B is a persistent and progressive inflammatory liver disease caused by infection with the hepatitis B virus (HBV). More than 240 million individuals are infected with HBV worldwide and hepatitis B accounts for an estimated 650 000 deaths annually. Approximately up to 30{\%} of chronically infected patients will develop complications of HBV infection including, but not limited to, liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Currently approved therapies have improved clinical outcomes, but have a considerable side-effect profile, elevated cost, and a finite course of treatment. This has led to a growing interest in research for new therapies. As the mechanisms for HBV replication are becoming better understood, new potential targets have been discovered, leading to the development of new therapies. In this article, we describe the promising therapies that are under evaluation, showing their mechanisms of action, effects, and stage of development.",
author = "Serigado, {Joao M.} and Manhal Izzy and Kalia, {Harmit S.}",
year = "2017",
month = "5",
day = "19",
doi = "10.1097/MEG.0000000000000911",
language = "English (US)",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Novel therapies and potential therapeutic targets in the management of chronic hepatitis B

AU - Serigado, Joao M.

AU - Izzy, Manhal

AU - Kalia, Harmit S.

PY - 2017/5/19

Y1 - 2017/5/19

N2 - Chronic hepatitis B is a persistent and progressive inflammatory liver disease caused by infection with the hepatitis B virus (HBV). More than 240 million individuals are infected with HBV worldwide and hepatitis B accounts for an estimated 650 000 deaths annually. Approximately up to 30% of chronically infected patients will develop complications of HBV infection including, but not limited to, liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Currently approved therapies have improved clinical outcomes, but have a considerable side-effect profile, elevated cost, and a finite course of treatment. This has led to a growing interest in research for new therapies. As the mechanisms for HBV replication are becoming better understood, new potential targets have been discovered, leading to the development of new therapies. In this article, we describe the promising therapies that are under evaluation, showing their mechanisms of action, effects, and stage of development.

AB - Chronic hepatitis B is a persistent and progressive inflammatory liver disease caused by infection with the hepatitis B virus (HBV). More than 240 million individuals are infected with HBV worldwide and hepatitis B accounts for an estimated 650 000 deaths annually. Approximately up to 30% of chronically infected patients will develop complications of HBV infection including, but not limited to, liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Currently approved therapies have improved clinical outcomes, but have a considerable side-effect profile, elevated cost, and a finite course of treatment. This has led to a growing interest in research for new therapies. As the mechanisms for HBV replication are becoming better understood, new potential targets have been discovered, leading to the development of new therapies. In this article, we describe the promising therapies that are under evaluation, showing their mechanisms of action, effects, and stage of development.

UR - http://www.scopus.com/inward/record.url?scp=85019543907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019543907&partnerID=8YFLogxK

U2 - 10.1097/MEG.0000000000000911

DO - 10.1097/MEG.0000000000000911

M3 - Article

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

ER -